MX9300664A - Formas de dosis farmaceuticas que contienen liberacion prolongada de ingrediente activo. - Google Patents

Formas de dosis farmaceuticas que contienen liberacion prolongada de ingrediente activo.

Info

Publication number
MX9300664A
MX9300664A MX9300664A MX9300664A MX9300664A MX 9300664 A MX9300664 A MX 9300664A MX 9300664 A MX9300664 A MX 9300664A MX 9300664 A MX9300664 A MX 9300664A MX 9300664 A MX9300664 A MX 9300664A
Authority
MX
Mexico
Prior art keywords
dosage forms
pharmaceutical dosage
forms containing
active ingredient
prolonged release
Prior art date
Application number
MX9300664A
Other languages
English (en)
Inventor
Sabine Compassi
Original Assignee
Siegfried Ag Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siegfried Ag Pharma filed Critical Siegfried Ag Pharma
Publication of MX9300664A publication Critical patent/MX9300664A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Esta invención se refiere a formas de dosificación farmacéuticas que contienen una velocidad de liberación lineal del orden O/0; para la administración oral, una vez del calcio del tipo de la dihidropiridina, caracterizado por una matriz homogénea que contiene 2-50 en peso de hodroxipropil-metilcelulosa que tiene un peso molecular promedio de 20,000-250,000, 5-60 en peso de un antagonista del calcio del tipo de dihidropiridina, así como excipientes acostumbrados, compatibles con la formulación, tales como controladores de la liberación lipofílica o hidrofílica, rellenadores agentes regulares del flujo lubricantes y, opcionalmente, revestimientos de película.
MX9300664A 1992-02-17 1993-02-08 Formas de dosis farmaceuticas que contienen liberacion prolongada de ingrediente activo. MX9300664A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH46492 1992-02-17

Publications (1)

Publication Number Publication Date
MX9300664A true MX9300664A (es) 1994-07-29

Family

ID=4187618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300664A MX9300664A (es) 1992-02-17 1993-02-08 Formas de dosis farmaceuticas que contienen liberacion prolongada de ingrediente activo.

Country Status (12)

Country Link
US (1) US5439687A (es)
JP (1) JPH061716A (es)
CA (1) CA2086989A1 (es)
CZ (1) CZ285177B6 (es)
FI (1) FI930657A (es)
HU (1) HU222252B1 (es)
IL (1) IL104192A (es)
MX (1) MX9300664A (es)
NO (1) NO302216B1 (es)
PL (1) PL172361B1 (es)
RU (1) RU2122413C1 (es)
SK (1) SK9793A3 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
JP2676319B2 (ja) * 1994-02-09 1997-11-12 大洋薬品工業株式会社 塩酸ニカルジピンの徐放剤用製剤およびこれを利用した徐放化製剤
MX9801835A (es) * 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
HUP0104472A3 (en) 1999-09-30 2002-12-28 Penwest Pharmaceuticals Co Pat Sustained release matrix systems for highly soluble drugs
KR100379299B1 (ko) * 2000-01-15 2003-04-10 주식회사 중외제약 펠로디핀의 가용화 방법 및 방출제어형 제제
US20030180354A1 (en) * 2001-10-17 2003-09-25 Dr. Reddy's Laboratories Limited Amlodipine maleate formulations
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
BE1014922A3 (nl) * 2002-03-01 2004-06-01 Pfizer Ltd Amlodipine als vrije base.
AU2003230805A1 (en) * 2002-04-05 2003-10-27 Penwest Pharmaceuticals Co. Sustained release metoprolol formulations
ATE408400T1 (de) * 2002-05-21 2008-10-15 Watson Lab Inc Pharmazeutische zusammensetzung mit verzögerter freisetzung
JP4563642B2 (ja) * 2002-05-31 2010-10-13 ワトソン ラボラトリーズ、インコーポレイテッド 医薬製剤
AU2003265446A1 (en) * 2002-08-13 2004-02-25 Medtronic, Inc. Active agent delivery system including a hydrophilic polymer, medical device, and method
ATE437634T1 (de) * 2004-01-14 2009-08-15 Lavipharm Lab Inc Transdermale abgabevorrichtung für dihydropyridin-artige calcium-antagonisten mit 2 fettsäuren
CA2568378C (en) * 2004-05-28 2013-03-19 Abbott Gmbh & Co. Kg Formulation obtained from a powder mixture comprising an inorganic pigment
US20060210623A1 (en) * 2005-03-17 2006-09-21 Stach Paul E Sustained release delivery of isradipine
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128280A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20080057123A1 (en) 2006-08-30 2008-03-06 Jagotec Ag Controlled Release Formulations
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
CA2677053C (en) * 2007-01-31 2016-03-15 Methylation Sciences International Srl Extended release pharmaceutical formulations of s-adenosylmethionine
JP4864024B2 (ja) * 2008-02-15 2012-01-25 エスエス製薬株式会社 時限放出製剤
KR20100069170A (ko) * 2008-12-16 2010-06-24 삼일제약주식회사 라시디핀 함유 과립 및 이를 포함하는 약학 조성물
KR101136075B1 (ko) * 2009-06-30 2012-04-17 케이엘피앤지씨앤팜 주식회사 고혈압 치료제 조성물
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
PL389530A1 (pl) 2009-11-10 2011-05-23 Fabryka Maszyn FAMUR Spółka Akcyjna Sposób przeniesienia napędu w kombajnie górniczym ścianowym
WO2019004448A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
CN112592311B (zh) * 2021-01-03 2023-01-31 迪沙药业集团有限公司 一种硝苯地平a晶块状晶习及其控释片组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
GB8722306D0 (en) * 1987-09-22 1987-10-28 Aps Research Ltd Sustained-release formulation
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
SI8810082A8 (en) * 1988-01-18 1995-12-31 Lek Tovarna Farmacevtskih Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
US4893393A (en) * 1988-10-25 1990-01-16 Marshall Ben C Pipe fitting assembly tool

Also Published As

Publication number Publication date
FI930657A0 (fi) 1993-02-15
IL104192A0 (en) 1993-05-13
HU9300424D0 (en) 1993-05-28
CA2086989A1 (en) 1993-08-18
SK9793A3 (en) 1993-09-09
PL297747A1 (en) 1993-11-02
HUT64694A (en) 1994-02-28
RU2122413C1 (ru) 1998-11-27
JPH061716A (ja) 1994-01-11
US5439687A (en) 1995-08-08
NO302216B1 (no) 1998-02-09
CZ8193A3 (en) 1994-01-19
HU222252B1 (hu) 2003-05-28
NO930543L (no) 1993-08-18
NO930543D0 (no) 1993-02-16
PL172361B1 (pl) 1997-09-30
IL104192A (en) 1998-01-04
FI930657A (fi) 1993-08-18
CZ285177B6 (cs) 1999-06-16

Similar Documents

Publication Publication Date Title
MX9300664A (es) Formas de dosis farmaceuticas que contienen liberacion prolongada de ingrediente activo.
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
RU93004469A (ru) Формы дозирования, обеспечивающие продленное выделение активного ингредиента
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR040245A1 (es) Formas de dosificacion y composiciones para administracion osmotica de dosificaciones variables de oxicodone
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
EA200300045A1 (ru) Композиция и лекарственная форма для задерживаемого желудочного выделения алендроната и/или других бис-фосфонатов
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
CO5640072A2 (es) Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion
AR066313A2 (es) Una formulacion de liberacion controlada de galantamina, una forma farmaceutica de dosificacion, un proceso para la preparacion de dicha formulacion, y el uso de dicha formulacion para la manufactura de un medicamento
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
UY27908A1 (es) Formulaciones y formas de dosificación para la administración controlada de topiramato
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
NO891680L (no) Osmotisk kontinuerlig avgivende oralt avgivelsessystem inneholdende et farmasoeytisk akseptabelt aktivt middel som har forbedrede kjernemembran-adhesjonsegenskaper.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ATE549015T1 (de) Pharmazeutische wirkstoffhaltige formulierung mit überzug
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
BRPI0411413A (pt) composições para revestimento entérico de um produto natural e de microcápsulas com revestimento entérico contendo lectina
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
BR0211198A (pt) Composições farmacêuticas e seu uso
HUP0500097A2 (hu) Nyújtott/szabályozott hatóanyag-leadású szilárd készítmény, mint kisebb dózisveszteséget mutató új hatóanyag-adagoló rendszer

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: VANTICO AG

MM Annulment or lapse due to non-payment of fees